Trial Profile

Prospective Analysis of Immunogenicity of the Nonavalent Human Papillomavirus Vaccination (GARDASIL 9) in Patients Post Solid Organ Transplant

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs V 503 (Primary)
Indications Human papillomavirus infections
Focus Pharmacodynamics

Most Recent Events

27 Sep 2024 Planned number of patients changed from 100 to 30.
27 Sep 2024 Number of treatment arms are decreased from 2 to 1 by the removal of Active Comparator: Group 1 (Patients prior to renal transplant). Study design is changed from parallel to single group assignment. Planned enrollment is also decreased.
09 Aug 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com